Estrogen-dependent alterations in D2/D3-induced G protein activation in cocaine-sensitized female rats.
Estrogen potentiates behavioral sensitization to cocaine in the female rat by mechanisms that remain undetermined. In this study, functional receptor autoradiography was used to investigate estrogen modulation of D2/D3 receptor-induced G protein activation in components of the reward pathway of female rats treated acutely and repeatedly with cocaine. Rats were ovariectomized and given an empty (OVX group) or estradiol benzoate-filled (OVX-EB group) implant. After a week, animals received a daily saline or cocaine injection (15 mg/kg, i.p.) for 5 days, and again on day 13. Animals were killed, and brains were removed and cryosectioned. D2/D3-stimulated [35S]guanosine 5'-(gamma-thio) triphosphate (GTPgammaS) binding was assessed in the cingulate cortex area 2 (Cg2), striatum (STR), nucleus accumbens (NAc) and ventral tegmental area (VTA). OVX-EB rats showed more [35S]GTPgammaS binding in the Cg2 and lower binding in the VTA than OVX rats; in the VTA this effect was reversed by a single cocaine injection. Repeated cocaine administration had opposite effects in OVX and OVX-EB rats. [35S]GTPgammaS binding was decreased in the Cg2, NAc and STR of OVX-EB rats, and increased in OVX rats. The present results support the hypothesis that cocaine-induced changes in D2/D3 receptor activation are regulated by estrogen. These data suggest that changes in D2/D3 receptor function represent one mechanism by which estrogen regulates behavioral sensitization to cocaine.
Febo
Marcelo
M
Laboratory of Neuroendocrinology, Department of Physiology, University of Puerto Rico, School of Medicine, San Juan, Puerto Rico.
González-Rodríguez
Loida A
LA
Capó-Ramos
David E
DE
González-Segarra
Naggai Y
NY
Segarra
Annabell C
AC
D000818:Animals; D001345:Autoradiography; D001522:Behavior, Animal / Q000187:drug effects; D001667:Binding, Competitive / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D003042:Cocaine / Q000494:pharmacology*; D018491:Dopamine Agonists / Q000494:pharmacology; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D004334:Drug Administration Schedule; D004343:Drug Implants; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D019204:GTP-Binding Proteins / Q000378:metabolism*; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000493:pharmacokinetics; D010052:Ovariectomy; D019257:Quinpirole / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D050637:Receptors, Dopamine D3; D012201:Reward; D013462:Sulfur Radioisotopes
D018491:Dopamine Agonists; D018765:Dopamine Uptake Inhibitors; C493595:Drd3 protein, rat; D004343:Drug Implants; D004967:Estrogens; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D013462:Sulfur Radioisotopes; C074283:estradiol 3-benzoate; D019257:Quinpirole; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D004958:Estradiol; D019204:GTP-Binding Proteins; D003042:Cocaine